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Regulation of mitochondrial protein expression is
crucial for the function of the oxidative phosphoryla-
tion (OXPHOS) system.Although thebasalmachinery
for mitochondrial transcription is known, the regula-
tory mechanisms are not completely understood.
Here, we characterized mTERF2, a mitochondria-
localized homolog of the mitochondrial transcription
termination factor mTERF1. We show that inactiva-
tion of mTERF2 in the mouse results in a myopathy
and memory deficits associated with decreased
levels of mitochondrial transcripts and imbalanced
tRNA pool. These aberrations were associated with
decreased steady-state levels of OXPHOS proteins
causing a decrease in respiratory function. mTERF2
binds to the mtDNA promoter region, suggesting
that it affects transcription initiation. In vitro interac-
tion studies suggest that mtDNA mediates interac-
tions between mTERF2 and mTERF3. Our results
indicate that mTERF1, mTERF2, and mTERF3 regu-
late transcription by acting in the same site in the
mtDNA promoter region and thereby mediate fine-
tuning of mitochondrial transcription and hence
OXPHOS function.
INTRODUCTION
The mitochondrial oxidative phosphorylation (OXPHOS) system
provides the majority of the cellular ATP. A better understanding
of the regulation of OXPHOS function is important at both biolog-
ical and clinical levels. Mitochondrial disorders have an esti-
mated incidence of 1:5000 live births (Schaefer et al., 2008)
and are associated with mutations in one of the 85 structural
genes or in genes involved in the biogenesis of the OXPHOS
complexes. Although the majority of these genes are encoded
in the nucleus, the mitochondrial DNA (mtDNA) encodes for 13
catalytically important proteins, 22 tRNAs, and 2 rRNAs
(Figure 1). Transcription of the nuclear genes is regulated by
several transcription factors (e.g., nuclear respiratory factors 1
and 2 [NRF1 and NRF2]), which are modulated by coactivators
such as the peroxisome proliferator-activated receptor g
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A(PPARg) coactivator a (PGC-1a) (Scarpulla, 2008). Mitochondrial
transcription is regulated both at the initiation and termination
level, but these processes are not completely understood. In
human mtDNA, transcription of the heavy strand (H strand) is
initiated from two specific and differentially regulated sites, H
strand promoters 1 and 2 (HSP1 and HSP2) (Montoya et al.,
1982) (Figure 1A). HSP2 transcription initiation site is located
close to the 50 end of the 12S rRNA gene and produces a polycis-
tronic RNA that corresponds to almost the entire H strand,
covering the 2 rRNA gene and 12 mRNA encoding gene. The
HSP1 site is located 16 bp upstream of tRNAPhe and 100 bp
upstream of HSP2. HSP1 transcription produces a transcript
that covers the tRNAPhe, tRNAVal, and the two rRNA genes and
terminates at the tRNALeu(UUR) gene. The basal transcription
machinery consists of mitochondrial RNA polymerase
(POLRMT), transcription factor A (TFAM), and either mitochon-
drial transcription factor B1 or B2 (TFB1/2). These components
are sufficient to initiate transcription in vitro (PMID: 17189185).
However, regulation of mitochondrial transcription and hence
OXPHOS function in vivo remains to be elucidated.
Termination of the H strand transcription unit is regulated by
the mitochondrial termination factor (mTERF1). mTERF1 binds
a 44 bp oligonucleotide at the boundary between 16S rRNA
and tRNALeu and is believed to be responsible for termination
of transcription at this site, thereby providing the relatively higher
levels of rRNA necessary for translation (Daga et al., 1993). The
mechanisms involved in transcriptional termination at the end
of the polycistronic transcript are not known.
Interest in studying mTERF1 increased after the A3243G point
mutation present in MELAS syndrome was reported to be asso-
ciated with decreased affinity binding of mTERF1 to the mtDNA
in vitro (Hess et al., 1991). A recent report demonstrated that
mTERF1 is able to bind mtDNA not only at the termination but
also at the initiation site, suggesting a loop model for transcrip-
tion termination (Figure 1B). Binding at the initiation site was
not observed with recombinant mTERF1 but only with fractions
extracted from cells (Martin et al., 2005).
This finding suggests that additional transcription factors or
posttranslational modifications are required for the regulation
of mitochondrial transcription. Likely candidates are members
of a family of highly conserved proteins containing mTERF-like
motifs, which were recently identified by bioinformatics tools
(Linder et al., 2005). mTERF1 and mTERF2 are present only in
vertebrates, whereas mTERF3 and mTERF4 are encountered
in all metazoans. Recently, the mammalian mTERF3 has been
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mTERF2 Is a Modulator of OXPHOS Functionproposed to be a negative regulator of mtDNA transcription
(Park et al., 2007).
In the present work, we show that mTERF2 is a mitochondrial
protein involved in the regulation of mitochondrial transcription,
thereby modulating OXPHOS function in mammals.
RESULTS
mTERF2 Is a Mitochondrial Protein Localized
in the Matrix
We used the online software TargetP to predict the subcellular
localization of the mouse mTERF2 protein. The score (0.82)
showed a high probability of mitochondrial localization. Tran-
scripts for mTERF2 were ubiquitously expressed (Figure 2A),
but relatively high levels of RNA expression were detected in
heart, brain, kidney, and testis, tissues with a high energy
demand (Figure 2A).
To verify mitochondrial localization of mTERF2, we expressed
an HA-tagged version of mouse mTERF2 in COS cells and
Figure 1. Mitochondrial DNA: Genes and Transcripts
(A) Circular human mtDNA. The D loop harbors the L strand
promoter (LSP), the H strand promoter (HSP), and the origin
of H strand synthesis (OH). The major L strand origin (OL) is
located in the ‘‘WANCY’’ cluster of tRNAs. In humans, a
second H strand promoter (HSP2) is located in the tRNAPhe
(F) immediately upstream of the 12S rRNA. Genes transcribed
from the H strand or the L strand are labeled on the outside
and inside of the circle, respectively (with modification after
Bonawitz et al., 2006). Binding sites of mTERF1 and mTERF3
are indicated.
(B) Transcription initiation complexes comprised of POLRMT,
TFAM, and one of the two TFB isoforms are assembled at LSP
and HSP. mTERF1 bind simultaneously HSP1 and TERM, re-
sulting in looping out of the 12S and 16S rRNA (with modifica-
tions after Martin et al., 2005).
tracked its intracellular localization by immuno-
cytochemistry. The localization of the mTERF2
protein overlapped with the MitoTracker dye, indi-
cating that mTERF2 is a mitochondrial protein (Fig-
ure 2B). Using a polyclonal antibody developed
against recombinant mTERF2, we found that
mTERF2 was not detected in the cytosolic fraction,
and it was protected from proteinase K digestion in
isolated heart mitochondria (not shown). We sub-
fractionated mouse heart mitochondria to further
analyze the localization of mTERF2 (Figure 2C). Mi-
toplasts treated with proteinase K showed a signal
for mTERF2, suggesting localization in thematrix or
in the inner mitochondrial membrane. Addition of
Triton X to the mitoplast preparation allowed
proteinase K to digest mTERF2. After submito-
chondrial fractionation, mTERF2 was predomi-
nantly found in the matrix fraction, a localization
pattern comparable to the matrix protein HSP60
and different from the inner membrane protein
COX4, a subunit of the membrane-embedded
cytochrome c oxidase (Figure 2C). We concluded
from these data that mTERF2 is amitochondrial protein localized
in the matrix.
BecausemTERF2contains conserved leucine zipper domains,
we asked whether mTERF2was able to form oligomers. We sub-
jected a mitochondrial protein extract (using 0.5% digitonin and
0.2 M KCl) to differential centrifugation in sucrose gradients.
mTERF2 was identified by immunoblotting in the 80 kDa fraction
(Figure S1A). Since mTERF2 has a predicted molecular weight of
39 kDa, the presence in a higher molecular weight complex sug-
gested thatmTERF2canoligomerize in vivo.When themitochon-
drial proteinswere extractedwith high salt conditions (0.7MKCl),
themTERF2 peak shifted to the fraction corresponding to 40 kDa
(Figure S1B). To determine whether mTERF2 is able to dimerize,
we carried out gel filtration chromatography experiments using
recombinant mTERF2. mTERF2 was eluted in a peak that corre-
sponds to 90 kDa, suggesting that mTERF2 was able to form
dimers in vitro (Figure S1C). Our findings are in concordance
with the presence of coiled-coil domains in mTERFD3 structure
that are likely involved in protein-protein interactions.
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mTERF2 Is a Modulator of OXPHOS FunctionConstruction of the mTERF2 Knockout Mice
To analyze the function of this newly identified mitochondrial
protein in vivo, we produced a mouse deficient in mTERF2 by
a gene trap strategy using an embryonic stem cell clone
(OST453159) that contains a viral insert between exons 2 and 3
of themTERF2 gene (Figures S1A and S1B). In animals homozy-
gous for themTERF2 allele containing the viral trap, no mTERF2
mRNA or protein could be detected in several tissues (Figures
S1C and S1D). This finding indicates that the viral trap success-
fully disrupted themTERF2gene.Because of its location, the viral
trap is not expected to affect neighboring genes (Figure S1B).
mTERF2 Knockout Mice Develop a Myopathy
and Memory Deficits
Loss of mTERF2 did not affect the life span and did not
significantly alter basal metabolism and heat production
Figure 2. Expression Profile and Mitochondrial Localization of
mTERF2
(A) Northern blot analysis of mTERF2 expression in different mouse tissues. A
single transcript of 1.1 kb was present in all investigated tissues. b-actin was
used as loading control.
(B) Confocal microscopy to determine subcellular localization of mouse
mTERF2. HA-tagged mTERF2 was expressed in COS cells and stained with
an anti-HA antibody (FITC 2nd antibody). MitoTracker red stain was used for
colocalization.
(C) Submitochondrial localization of mTERF2 in heart mitochondria. mTERF2
has a localization pattern comparable to the matrix protein HSP60 and
different from the inner membrane COX4.
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RA(Figure S2A). A tendency for a decreased body weight for both
female and male mTERF2 knockout (KO) mice compared to
wild-type (WT) controls (Figure 3A) was observed, with a more
drastic effect seen in the female animals. A tendency for
decreased body fat content was observed for female mTERF2
KO mice, but no significant effect could be detected for the
male animals (Figure S2B).
Because the mTERF2 KO mice did not develop an overt
phenotype, we metabolically challenged the mice by feeding
them with a ketogenic (high-fat, low-carb) diet (KD). Ketone
bodies produced by the KD by fatty acid oxidation bypass
glycolysis and enter the citric acid cycle to produce OXPHOS
substrate. Mice on the KD rely more on fatty acid oxidation
and OXPHOS for ATP production than mice on a standard
high-carbohydrate diet (Laffel, 1999). Hence, we hoped that
OXPHOS defects, which might be masked by the sedentary life-
style of the laboratory mice, would become more evident when
the mice are fed a KD.
In a treadmill test, 6-month-old mTERF2 KO animals fed
a standard diet (SD) showed increased number of falls within
4 min compared to controls (Figure 3B). Grip strength tests
confirmed a tendency for muscle weakness in the mTERF2 KO
mice (Figure S2C). KO mice challenged by the KD showed
a more pronounced phenotype: the KD-fed mTERF2-deficient
mice fell nearly twice asmuch as the SD-fed KOmice (Figure 3B).
The observed myopathic phenotype was also evident in an
endurance test: while SD-fed mTERF2 KO mice managed to
run approximately three-fourths of the distance traveled by the
controls, the KD-challenged KO mice could run only 50% of
the distance (Figure 3C). We also analyzed whether memory
and orientation skills were affected upon loss of mTERF2 by
testing mTERF2 KO and control mice in a spatial water maze.
The maze consisted of a round pool with six arms, one of them
with a hidden a platform. Both number of mistakes (entering
the wrong arm) and traveling time to the platform were recorded.
While no significant changes were observed for the unchal-
lenged mTERF2 KO mice, KD-fed KO mice showed memory
and orientation deficits: they made more mistakes and needed
a longer time to find the platform (Figure 3D). Neither SD- nor
KD-fed mTERF2 KO mice showed signs of exhaustion during
the 60 s intervals of training and test, so the observed deficits
are likely caused by defects in cognition.
Loss of mTERF2 Causes a Respiratory Defect
in Certain Tissues
Since we observed defects in exercise and memory perfor-
mance, we assumed that the loss of mTERF2 affects both
muscle and brain, two high-energy-demand tissues that mainly
rely on OXPHOS function. To test for an OXPHOS impairment
caused by the loss of mTERF2, we analyzed the growth of lung
fibroblasts from animals deficient in mTERF2 compared to
controls. A cell line obtained from the mTERF2 KO animals
showed a drastically reduced growth rate in the galactose media
compared to the controls, indicating anOXPHOS defect (Figures
4A and 4B). Growth in glucose-based media remained
unchanged (Figure S3B).
To further analyze the OXPHOS defect, we measured COX
and complex I + III (CI + III) activities as markers for OXPHOS
function in mitochondria isolated from skeletal muscle, liver,
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mTERF2 Is a Modulator of OXPHOS FunctionFigure 3. mTERF2 KO Mice Gain Less Weight than WT Controls and Show Signs of a Myopathy
(A) Weight gain for male and female mTERF2 KO mice and WT controls (N = 6 each).
(B and C) Treadmill performance (B) and endurance test (C) of KO and control mice (N = 6 each) at 6 months of age on a standard (SD) or a ketogenic (KD) diet.
(D) Spatial water maze test of KO and control mice (N = 6 each) at 6 months of age on SD or KD. Number of mistakes and time until finding the platform were
recorded. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars for (A)–(D) are SEM.
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heart, kidney, cortex, hippocampus, and cerebellum. In the
unchallenged mice, we could detect only a reduction of COX
and CI + III activity in skeletal muscle of mTERF2 KO mice,
whereas the other tissues were unaffected by the loss of
mTERF2. In skeletal muscle, the COX activity of the mTERF2-
deficient sample was reduced to 40% of the WT controls,
whereas the CI + III activity was decreased to 30% of the
control (Figures 4C and 4D).
In the KD-fed mice, loss of mTERF2 resulted in an OXPHOS
defect of several tissues: besides skeletal muscle, cortex, hippo-
campus, cerebellum, liver, and kidney showed a reduction of
COX activity to 20%–60% of the control (Figure 4C). Skeletal
muscle and hippocampus were most affected, with only 20%
of WT COX activity. CI + III was also largely decreased in skeletal
muscle, cortex, hippocampus, cerebellum, liver, and kidney.
Again, skeletal muscle was the most severely affected and
showed only 30% of the control activity. The other tissues re-
tained 50%–70% of the WT CI + III activity (Figure 4D). We
found the same trend in fibroblasts deficient in mTERF2, where
RE502 Cell Metabolism 9, 499–511, June 3, 2009 ª2009 Elsevier Inc.complex I + III and COX activities were reduced to 50% of
the WT rate (Figure S3B). Surprisingly, in both the SD- and the
KD-fed mice, OXPHOS of heart mitochondria was unaffected
by loss of mTERF2, as indicated by the unchanged COX and
CI + III activities (Figures 4C and 4D).
Loss of mTERF2 Results in Decreased Levels
of OXPHOS Complexes
To investigate the cause of the OXPHOS defect in mTERF2 KO
mice, we analyzed the steady-state levels of the different
OXPHOS complexes. Western blot analyses of skeletal muscle
mitochondria, using antibodies against different subunits of
OXPHOS protein, showed that steady-state levels of subunits
from complexes I, III, IV, and V were decreased in both the SD-
and KD-fed mTERF2 KO mice (Figures 4E and 4F), consistent
with the reduced OXPHOS function in mitochondria. Whereas
the unchallenged mTERF2 KO mice showed a decrease to
60%–80% of the WT levels of subunits of complexes I (ND39),
IV (COX1), and V (ATPb), these levels were even more decreased
Cell Metabolism
mTERF2 Is a Modulator of OXPHOS Functionin the KD-challenged KO mice, to 40%–60% of WT (Figures 4E
and 4F).
We performed Blue Native (BN) immunoblots of mitochondria
from challenged mTERF2 KO and WT controls to analyze
changes in the levels of the native OXPHOS complexes. Using
this approach, we detected a 50% decrease in the levels of
the OXPHOS complexes (Figures 4G and 4H), confirming the
OXPHOS defect in the mTERF2-deficient mice.
mTERF2 Deficiency Triggers Compensatory Responses
OXPHOS dysfunction is often accompanied by mitochondrial
proliferation as a compensatory mechanism for the impaired
mitochondrial function. We measured citrate synthase (CS)
activity, a well-knownmarker for mitochondrial mass, in different
tissues of SD- and KD-fedmTERF2 KOmice to investigate if loss
of mTERF2 also initiates this compensatory mechanism. In the
unchallenged KO mice, we found an 2-fold increase in the
CS activity compared to the controls, in skeletal muscle only
(Figure 5A), consistent with the finding that only this tissue
showed an OXPHOS defect (Figures 4A and 4B) in the unchal-
lenged state. However, when the mTERF2-deficient mice were
Figure 4. Loss of mTERF2 Causes an
OXPHOS Deficiency
(A and B) Growth rates of control and mTERF2 KO
fibroblasts were recorded in media supplemented
with galactose (N = 3 for each time point).
(C and D) Cytochrome c oxidase (COX) and CI + III
activity in mitochondria isolated from different
tissues of 6-month-old mTERF2 KO mice fed SD
or KD. The dashed line indicates the activity of
SD- or KD-fed control (N = 3 for each group).
(E and F) Quantification of mitochondrial protein
steady-state levels in muscle mitochondria
mTERF2 KO and control mice by western blot on
SD or KD (N = 3 for each group). The blot shows
samples from KD-fed animals. The dashed line
indicates the SD- or KD-fed control. Error bars
for (A)–(F) are SEM.
(G and H) BN immunoblotting and quantification of
OXPHOS complexes of skeletal muscle mitochon-
dria from mTERF2 KO and control mice (N = 3) on
KD. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars
for (H) are SEM.
challenged with the KD, all examined
tissue homogenates except heart
showed significant increase in CS activity
(Figure 5A), consistent with the pattern
observed for OXPHOS defects (Figure 4).
While the KD did not further increase CS
activity in skeletal muscle of KO mice
(2-fold), cortex showed a 4- to 5-fold
increase compared to the WT control.
CS activity of hippocampus, cerebellum,
liver, and kidney from KD-fed mTERF2
KO mice was increased 1.5- to 2-fold
relative to WT controls on the same diet.
CS activity in mitochondria from KD-fed
WT mice was 3- to 3.5-fold increased
compared to SD-fed WT controls in liver and muscle.
We then used electron microscopy to further investigate the
degree and nature of the mitochondrial proliferation in the most
affected tissue of mTERF2 KO mice, the skeletal muscle. We
observed an increased number of mitochondria in the mTERF2
KOmuscle sample. Thesemitochondriawere enlarged compared
to the WT control and had an abnormal shape (Figure 5B).
We next asked whether the loss of mTERF2 has an effect on
expression of genes involved in mitochondrial transcription or
of other mTERF homologs. In real-time PCR experiments, we
observed that proteins involved in mitochondrial gene expres-
sionwere upregulated as a result of the loss ofmTERF2. In skele-
tal muscle of unchallenged mTERF2 KO mice, mTERF3 was up-
regulated5-fold. Transcripts for mitochondrial marker proteins
porin and CS were both upregulated 1.5- to 2-fold in the KO
mice. Components of the mitochondrial TFB2, TFAM and RNA
polymerase (POLRMT) were also significantly upregulated
(Figure 5C). In the challenged mTERF2 KO mice, we found
a further increased expression of mTERF3 and TFB2 compared
to the unchallenged KO mice, while no further increase was
observed for TFAM and POLRMT. Additionally, we observed
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mTERF2 Is a Modulator of OXPHOS FunctionFigure 5. mTERF2 Deficiency Is Associated with Increased Mitochondrial Biogenesis and Upregulation of mTERF Homologs
(A) CS activity in homogenates of different tissue of 6-month-old mTERF2 KO and control mice (N = 3) on SD or KD. The dashed line indicates the SD- or KD-fed
control. Error bars are SEM.
(B) Electron micrograph from longitudinal sections taken from the gastrocnemius muscle from 12-month-old mTERF2 KO andWT control mice. Scale bar: 1 mm.
(C) Relative expression of mTERF1, mTERF3, mTERF4, mitochondrial RNA polymerase (POLRMT), transcription factors B1 (TFB1) and B2 (TFB2), mitochondrial
transcription factor A (TFAM), and the mitochondrial proteins porin and citrate synthase (CS) in skeletal muscle of 6-month-old mTERF2 KO and control mice
(N = 3). The dashed line indicates the SD- or KD-fed control.
(D) Relative quantification of mtDNA (ND1) versus nuclear DNA (b-actin) by quantitative PCR of DNA isolated from skeletal muscle of 6-month-old SD- and KD-fed
mTERF2 KO and control mice (N = 3). Values are normalized to the WT control on the same diet.
(E) Quantification of ATP in the different tissue of 6-month-old SD- and KD-fed mTERF2 KO and control mice (N = 3). Values are normalized to the WT control on
the same diet. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars for (C)–(E) are SEM.ET
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The upregulation of gene expression for proteins involved in
mitochondrial gene expression together with the observed mito-
chondrial proliferation may partially compensate for the impaired
mitochondrial function. Interestingly, a similar upregulation of the
mTERF proteins and components of themitochondrial transcrip-
tion machinery was observed in the heart of mTERF2 KO mice
(Figure S5).
In agreement with the upregulation of CS (Figure 5A), we saw
a marked increase of 3- to 3.5-fold of mtDNA content in skele-
tal muscle of mTERF2 KO mice on SD. When kept on KD, the
mtDNA content in the KO mice increased even further, to
4.5-fold of the WT control on the same diet. While mTERF2-
deficient mice showed no significant changes in mtDNA levels
in brain and liver, mice challenged with KD displayed an increase
R
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liver. mtDNA levels in heart remained unchanged in the mTERF2
KO mice in both the SD- and KD-fed states (Figure 5D).
Despite the mitochondrial proliferation in the skeletal muscle,
ATP levels were decreased to 60% of WT values for mTERF2
KOmice on the SD. ATP levels of other tissues for these animals
remained unaffected (Figure 5E), in line with the unchanged
OXPHOS function (Figures 4C and 4D). mTERF2 KO mice chal-
lenged by KD showed a even further decrease in ATP levels in
skeletal muscle, to 30% of the control value, in agreement
with the decreased OXPHOS function of the KD-fed mTERF2
deficient mice. The multitissue OXPHOS defects of the KD-fed
mTERF2 KOmice correlated with decreased ATP levels in brain,
liver, and kidney (Figure 5E). As observed for COX and CI + III
activity, the heart remained unaffected by loss of mTERF2.
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mTERF2 Is a Modulator of OXPHOS FunctionLoss of mTERF2 Causes a Decrease
in Mitochondrial mRNAs
The decrease in steady-state levels of the OXPHOS complexes,
the fact that mTERF2 is a homolog of mTERF1 and mTERF3,
and the upregulation of genes coding for proteins involved in
mitochondrial gene expression in the mTERF2 KO mice led us
to hypothesize that mTERF2 might be involved in the regulation
of mtDNA transcription. To test this hypothesis, we analyzed
mitochondrial protein synthesis in fibroblasts obtained from
mTERF2 KOmice andWT controls. We observed that mitochon-
drial protein synthesis was downregulated when mTERF2 was
lost. The levels of most mtDNA-encoded proteins were
decreased in the mTERF2-deficient fibroblasts. Most severely
affected were ND2, COX2, COX3, and ATP6, which showed
50% of the WT protein level (Figures 6A and 6B).
Figure 6. mTERF2 Deficiency Causes a
Decreased mtDNA Transcription and an
Imbalance of Mitochondrial tRNA Steady-
State Levels
(A and B) In vivo labeling (A) and quantification (B)
of mitochondrial translation products in mTERF2
KO and WT fibroblasts. VDAC was used as a
loading control. Error bars for (B) are SEM.
(C and D) Steady-state levels of mitochondrial
transcripts and the nuclear encoded CS in skeletal
muscle of SD- and KD-fed mTERF2 KO and WT
control mice (N = 3). The dashed line indicates
the SD- or KD-fed control. Error bars for (D) are
SEM.
(E) Steady-state levels of different mitochondrial
tRNAs originating from the HSP and LSP tran-
scripts in mTERF2-deficient and control muscle
(N = 3) on SD.
(F) The same experiment was performed with mice
fed the KD.
(G) Quantification of tRNA levels in muscle of
SD- and KD-fed mice. The dashed line indicates
the SD- or KD-fed control. *p < 0.05; **p < 0.01;
***p < 0.001. Error bars are SEM.
We further analyzed the role of
mTERF2 in mitochondrial transcription
by examining the steady-state levels of
mtDNA transcripts in skeletal muscle of
SD- and KD-fed animals. While the SD-
fed mice showed only mild changes in
all analyzed mRNAs (data not shown),
mitochondrial transcripts of the chal-
lengedmTERF2 KOmicemuscle showed
marked decreases for both heavy and
light strand transcripts (Figure 6B): sub-
units COX 1, 2, and 3 were decreased
to60%–80% of the control levels. ATP6
and Cytb mRNA levels were lowered to
60%–70%. Complex I subunits ND1,
ND4, and ND6 were most affected and
decreased to 20%–40% of the control
levels (Figures 6C and 6D). Because we
observed an 1.5-fold increase in the
mRNA levels of the mitochondrial marker
CS in challenged mTERF2 mice, the observed decreases of the
mitochondrial transcripts in total muscle RNA might be underes-
timated due to the mitochondrial proliferation.
Next, we analyzed the steady-state levels of mitochondrial
tRNAs in skeletal muscle of SD- and KD-fed mTERF2 KO mice
andWTcontrols. In theunchallengedstate, lossofmTERF2caused
an imbalance of the tRNA levels derived from both transcripts. Of
the analyzed H strand transcripts, the levels of tRNALeu(UUR) and
tRNAPhe were increased, with the most drastic effect seen for
phenylalanine, which showed a nearly 2-fold increase in steady-
state levels in the mTERF2 KO (Figure 6E). In contrast, the levels
of tRNAAsp and tRNALys were decreased. Of the analyzed L strand
transcripts, tRNAPro and tRNAGlu showed increased levels in the
mTERF2 KO samples, whereas tRNASer and tRNAGln were
decreased (Figure 6E). Similar trends were seen for tRNA levels in
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mTERF2 Is a Modulator of OXPHOS FunctionmTERF2-deficient fibroblasts (Figure S3D). The tRNA levels in the
KD-challenged mTERF2 KO mice were also imbalanced, but in
amoreconsistentpattern.With theexceptionof tRNAPhe,which re-
mained unchanged, the levels of all other examined tRNAs were
markedly decreased to 40%–60% of the tRNA levels of KD-fed
controls (Figure 6C).
We carried out an in vitro mitochondrial transcription assay
using mitochondrial extracts from WT and mTERF2-deficient
skeletal muscle. We observed that in the absence of mTERF2,
mitochondrial transcription is largely decreased (Figure S6).
mTERF2 Binds to the HSP Promoter Region of mtDNA
The decreased mitochondrial transcription caused by the loss of
mTERF2 suggests that mTERF2 might interfere with mitochon-
drial transcription by interacting with the regulatory elements of
mtDNA. To characterize the ability of mTERF2 to interact with
mtDNA, we performed electromobility shift assays (EMSAs).
Two regions known to be binding sites for mTERF were initially
investigated. We used recombinant mTERF1 and mTERF2 in
our EMSA studies. Unlike mTERF1, mTERF2 did not produce
a shift when incubatedwith a DNA fragment containing the termi-
nation site localized between 16S rRNA and tRNALeu(UUR).
However, mTERF2 produced a shift when incubated with
a 50 bp probe corresponding to the HSP region. We could
demonstrate the binding specificity by competition assays.
Addition of a 10-fold excess of unspecific DNA did not influence
the shift of the promoter-DNA fragment bymTERF2, whereas the
specific DNA competed out the labeled probe (Figure 7A). As
shown before for the recombinant protein, mTERF1 did not
show binding to the promoter region (Martin et al., 2005). These
findings suggest that mTERF2 possibly regulates mitochondrial
transcription by interacting with the mtDNA promoter region.
To further characterize the interaction of mTERF2 with regula-
tory elements of the mtDNA, we used mouse anti-FLAG anti-
body to perform chromatin immunoprecipitation (ChIP) on a
stable LMTK cell line expressing FLAG-tagged mTERF2. We
employed 16 primer pairs in the region from Cytb to ND1 to
screen the promoter and terminator regions of the mtDNA as
well as primer pairs in COX1, ND4, and ND5 to screen regions
outside the regulatory elements. For mTERF1, we detected the
previously described binding sites in the HSP promoter and in
the tRNALeu(UUR) site. For mTERF2, we observed an increased
signal in the HSP region (Figure 7B) that corresponded to the
DNA region used in the EMSA experiment (see above). No other
significant increase in signal was observed in the examined
regions, indicating that the HSP region is the only interaction
site of mTERF2 with mtDNA.
mTERF2 Coimmunoprecipitates with mTERF1
and mTERF3
According to ChIP analysis, the HSP region is a common binding
site for mTERF1, mTERF2, and mTERF3 (see above and Park
et al., 2007). This finding led us to explore possible interactions
between the three mTERF proteins. We used mitochondria puri-
fied from cell lines stably expressing mTERF2-FLAG/mTERF1-
HA. Using an anti-FLAG antibody directed against FLAG-tagged
mTERF2, we were able to coimmunoprecipitate mTERF1 and
mTERF3. Also, using an anti-HA antibody directed against the
HA-tagged mTERF1, we could detect mTERF2 and mTERF3 in
R506 Cell Metabolism 9, 499–511, June 3, 2009 ª2009 Elsevier Inc.the immunoprecipitate (Figure 7C). Importantly, we could not
coimmunoprecipitate the mitochondrial matrix protein, HSP60,
or an inner membrane protein, SDH, confirming the specificity
of the coimmunoprecipitation.
We next asked whether the coimmunoprecipitation of the
mTERF family members might be mediated by mtDNA. There-
fore, we expressed recombinant mTERF1, mTERF2, and
mTERF3 in bacteria andperformed coimmunprecipitation exper-
iments using mixture of bacterial lysates containing the different
mTERF proteins. We performed the assay in presence of liver
mtDNA and in the presence of an unrelated plasmid vector (V)
as a control. When HA-tagged mTERF1, HIS-tagged mTERF2,
and FLAG-taggedmTERF3weremixed, Ni-NTAmagnetic beads
(directed against 63HIS-tagged mTERF2) coimmunoprecipi-
tatedFLAG-taggedmTERF3 in thepresenceofmtDNA.However,
when mtDNA was replaced by the plasmid vector, we could not
detect an interaction between mTERF2 and mTERF3 (Figure 7D,
subpanel a). We detected the same kind of coimmunoprecipita-
tion of mTERF2 and mTERF3 in presence of mtDNA, when
a mixture of bacterial lysates containing HA-tagged mTERF1,
FLAG-taggedmTERF2, and HIS-taggedmTERF3 were coimmu-
noprecipitated by Ni-NTA beads (Figure 7D, subpanel b). Inter-
estingly, mTERF1 could not be immunoprecipitated in either
setup (Figure 7D, subpanels a and b). Importantly, both in the
absence or presence ofmtDNA,HA-taggedSOD1 failed to coim-
munoprecipitate with either HIS-tagged mTERF2 (Figure 7D,
subpanel c) or HIS-tagged mTERF3 (Figure 7D, subpanel c).
DISCUSSION
As recent reports suggest, the regulation of mitochondrial tran-
scription in vivo is likely to be complex. The humanmitochondrial
ribosomal protein MRPL12 has been identified as a stimulator of
transcription by directly interacting with POLRMT in vivo and
in vitro (Wang et al., 2007). mTERF3, an mTERF1 homolog, has
been proposed to be a negative regulator of mammalian mtDNA
transcription (Park et al., 2007). These findings highlight that
mitochondrial transcription regulation is more complex than
previously anticipated.
We identified another homolog of mTERF1, mTERF2, as
a novel modulator of mitochondrial transcription. mTERF2 is
a mitochondrial protein localized in the matrix compartment.
We found that loss of mTERF2 results in a defect in OXPHOS
complexes caused by decreased steady-state levels of the indi-
vidual OXPHOS complexes. The decreased steady-state levels
of the proteins were associated with decreased mRNA levels,
imbalanced tRNA levels, and decreased in vitro mitochondrial
transcription activity, suggesting that mTERF2 is a modulator
of mitochondrial transcription. In the mTERF2 KO animals, the
OXPHOS defect is probably partially counteracted by an
increased mitochondrial mass, as indicated by increased CS
activity and mtDNA levels.
The unchallenged mTERF2 KO mice displayed OXPHOS
impairment only in skeletal muscle, while the KD induced amulti-
tissue mitochondrial defect, with muscle displaying the greatest
sensitivity to the mTERF2 loss. It was surprising to us that we
could not detect any effect of the mTERF2 KO in heart, a tissue
that has high levels of mTERF2 mRNA expression. As a similar
pattern of upregulation of mTERF proteins and components of
C
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mTERF2 Is a Modulator of OXPHOS FunctionFigure 7. mTERF2 Binds Specifically the Promoter Region of mtDNA Together with mTERF1 and mTERF3
(A) Electromobility shift assays (EMSA) of recombinant mTERF1 and mTERF2 at the termination site (TERM) and promoter region (PROM) of mtDNA. mTERF2
binding to the promoter fragment is challenged with unspecific and specific DNA fragments.
(B) ChIP analysis with a monoclonal anti-FLAG antibody using stable cell lines expressing FLAG-tagged mTERF2 or mTERF1. The panel indicates the position of
the primer pairs in the Cytb-ND1 region used for the ChIP analysis. Additionally, primer pairs in COX1, ND4, and ND5 were used. Error bars are SEM.
(C) In vivo coimmunoprecipitation of mTERF1-mTERF2-mTERF3 complexes from LMTK cells. Shown are western blots of the input, anti-FLAG, and anti-HA anti-
body-mediated immunoprecipitations from untransfected LMTK cells and a stable LMTK line expressing FLAG-tagged mTERF2 and HA-tagged mTERF1. Input
lanes and immunoprecipitations were probed with anti-FLAG and anti-HA antibody. Specificity was analyzed by probing with antibodies directed against HSP60
(mitochondrial matrix protein) and succinate dehydrogenase (SDH, mitochondrial inner membrane protein).
(D) In vitro coimmunoprecipitation of recombinant mTERF1, mTERF2, and mTERF3 in presence and absence of mtDNA. Bacterial lysates expressing affinity-
taggedmTERF1, mTERF2, andmTERF3 andmtDNA or an unrelated plasmid vector, pcDNA3.1 (V), weremixed and coimmunoprecipitated with Ni-NTAmagnetic
beads. The following mixtures of bacterial lysate were used: a—HA-taggedmTERF1, HIS-taggedmTERF2, and FLAG-taggedmTERF3; b—HA-taggedmTERF1,
FLAG-tagged mTERF2, and HIS-tagged mTERF3; c—HIS-tagged mTERF2 and HA-tagged SOD1; d—HIS-tagged mTERF3 and HA-tagged SOD1.
(E) Model of transcription regulation bymTERF2 andmTERF3. InModel A, mTERF1, mTERF2, andmTERF3 bind simultaneously at HSP; in B, mTERF1 and either
mTERF2 or mTERF3 bind at HSP.
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Dthe mitochondrial transcription machinery was observed in both
heart and skeletal muscle, it seems likely that the heart either
possesses redundant mechanisms to circumvent the alteredmitochondrial transcription or is not as dependent on the parti-
cular regulation conferred by mTERF2. Apparently, mTERF2
exerts tissue-specific control of OXPHOS function. TissueCell Metabolism 9, 499–511, June 3, 2009 ª2009 Elsevier Inc. 507
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mTERF2 Is a Modulator of OXPHOS Functionspecificity of OXPHOS function has been observed before
(Rossignol et al., 2000). Tissue specificity has also been reported
in patients with mutations in mitochondrial translations factor
EFG1 (Antonicka et al., 2006).
It was intriguing to us that although loss of mTERF2 and
mTERF3 have opposite effects on the steady-state levels of
mitochondrial mRNAs (see above and Park et al., 2007), the
imbalance in tRNA levels was somehow similar. In the WT situa-
tion, tRNA levels are adjusted to optimize the rate and accuracy
of mitochondrial translation, and there is no strict correlation
between steady-state levels of tRNAs and rate of transcription
(King and Attardi, 1993). Apparently, disturbances in steady-
state levels of mRNA transcripts, either an increase (as for the
mTERF3 KO) or a decrease (as in the mTERF2 KO), disturb the
tRNA balance that might contribute to the observed defect in
mitochondrial function. The variable effects on the levels of the
individual tRNAs could be due to differences in RNA processing
and stability as well as imbalances caused by the decreases in
transcripts and hence in mitochondrial protein synthesis.
Interestingly, we found an increased expression of mTERF1
and mTERF3 in the mTERF2-deficient mice. mTERF1, 2, and 3
share a common binding site in the HSP region of mtDNA (see
above and Park et al., 2007), suggesting interdependence of
the three mTERF homologs. mTERF1 is involved in transcription
initiation and termination for synthesis of the rRNAs. mTERF3
was suggested to be a repressor of mtDNA transcription, as
loss ofmTERF3 resulted in increasedmRNA levels and disturbed
respiratory chain function (Park et al., 2007). Here, we show that
mTERF2 is also necessary to maintain normal levels of mito-
chondrial transcripts in mammals: loss of mTERF2 causes
decreased steady-state levels of mitochondrial transcripts, re-
sulting in impaired OXPHOS function. The different effects of
mTERF2 and mTERF3 on mitochondrial mRNA levels (mTERF2
KO: decreased mRNA levels; mTERF3 KO: increased mRNA
levels [Park et al., 2007]) and the fact that these opposite alter-
ations result in OXPHOS defects highlight that maintaining an
optimal balance of transcript levels is crucial for optimized mito-
chondrial function. It seems plausible that mTERF2 andmTERF3
have different regulatory roles in controlling and fine-tuning
mtDNA transcription to regulate OXPHOS function. We could
coimmunoprecipitate mTERF1, mTERF2, and mTERF3 in vivo.
Since all three mTERF proteins share the same mtDNA binding
site in the HSP region, this coimmunoprecipitation does not
necessarily demonstrate a direct association between the three
mTERF proteins. It is also possible that they coimmunoprecipi-
tate because they bind to the same mtDNA region. However,
the fact that the mtDNA binding sites are in the same region as
well as the ability of the mTERF1 and mTERF2 to oligomerize
(Asin-Cayuela et al., 2004 and above) led us to hypothesize
that this binding at the D loop region of two or more mTERF
proteins mediates the formation of a hetero-oligomer that regu-
lates and fine-tunes mitochondrial transcription initiation.
In mTERF3 KO mice, increased levels of mRNA transcription
were observed (Park et al., 2007). On the contrary, loss of
mTERF2 resulted in decreased levels of all mRNA transcripts
measured. The different effect of the mTERF2 and mTERF3
KOs on mRNA levels might indicate that these two mTERF
proteins modulate mitochondrial transcription in opposite
ways: mTERF2 might promote transcription initiation, while
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of the three mTERF proteins, different models for the regulation
are possible: (1) mTERF1, mTERF2, and mTERF3 bind simulta-
neously, or (2) mTERF1 and either mTERF2 or mTERF3 bind at
HSP with mTERF2 and mTERF3 binding regulating transcription
initiation (Figure 7E). In doing so, it is possible that mTERF2 and
mTERF3 could influence the assembly of the mitochondrial tran-
scription machinery and thus control transcription initiation.
Regulation of mRNA transcription by these factors might help
fine-tune OXPHOS function according to energy demands.
Neither mTERF2 nor mTERF3 bind to the L strand promoter
(LSP), but for both mTERF2 KO and mTERF3 KO, LSP tran-
scripts were affected (see above and Park et al., 2007). This
finding suggests that mTERF2 and mTERF3, although binding
to HSP, regulate transcription on both strands. This regulation
might be achieved by modulating each transcription event indi-
vidually by directly affecting transcription initiation at LSP and
HSP. It is also possible that transcription of only one of the
strands is regulated, which then might affect transcription from
the opposite strand. LSP is located in close proximity to the
promoter region HSP, hence raising the question of how tran-
scription from these opposing promoters can be initiated without
steric hindrance of the transcription machinery. The mTERF1
homologs DmTTF in Drosophila melanogaster and mtDBP in
the sea urchin have been implicated in regulating elongation of
overlapping transcription units in their mitochondrial genomes
(Polosa et al., 2007; Roberti et al., 2003). Thus, it is conceivable
that mTERF2 might act in a similar way and regulate elongation
of the transcripts from the opposing HSP and LSP. Transcription
initiation interference might occur more frequently if mTERF2 is
absent, resulting in reduced promoter activity, which leads to
the observed altered levels of transcripts. A similar mechanism
was also proposed for the function of mTERF3, where imbal-
anced tRNA and mRNA levels were observed (Park et al., 2007).
Although the somehow similar abnormalities in the steady-
state levels of tRNAs observed in mTERF2 and mTERF3 knock-
outs can be caused by posttranscriptional events, they can also
underlie a different mechanism of transcription regulation, still to
be uncovered.
Very recently, Pellegrini et al. (2009) showed that mTERF2 is
a mitochondrial nucleoid protein that is able to bind DNA.
However, in contrast to our findings, they did not identify specific
binding sites. Further studies should help clarify the specific
mechanism of mTERF2 regulation of mtDNA expression.
In conclusion, we identified and characterized mTERF2 as a
modulator ofmitochondrial transcription that affectsmitochondrial
transcript levels and hence OXPHOS function. The interdepen-
dence and interaction between mTERF1, mTERF2, and mTERF3
suggests that themTERFhomologs, togetherwith other regulatory
enzymes such MRPL12 and probably other unidentified proteins,
are responsible for fine-tuning mitochondrial transcription and
OXPHOS function. Moreover, this arsenal of mTERF homologs
may help specific tissues to adapt to their energetic demands.
EXPERIMENTAL PROCEDURES
Animal Husbandry
The mice were kept under conditions of 12 hr light/dark cycle at room temper-
ature. They were allowed access to a regular diet (Rodent Chow 5010, Harlan
CT
ED
Cell Metabolism
mTERF2 Is a Modulator of OXPHOS FunctionLaboratories; Indianapolis, IN) or to a KD (F3666, Bio-Serv; Frenchtown, NJ)
ad libitum. The KD was started at 6 weeks of age.
Behavioral Test
Treadmill performance and endurance tests were carried out as described
previously (Wenz et al., 2008). Spatial acquisition and retention was assessed
by Morris water maze test (Vorhees and Williams, 2006).
Generation of mTERF2 KO Mice
A gene trap with an insertion in the intron 2 of mTERF2 gene was purchased
from Lexicon Pharmaceuticals, Inc. (The Woodlands, TX) (Figures S2A and
S2B). The ES clone (OST 453159) was injected in blastocysts and implanted
in pseudopregnant mice at the University of Miami, Transgenic Animal Core
Facility (Miami). Genotyping of the mice was performed using primers de-
signed to amplify the WT and KO alleles. Mice were backcrossed to C57BL/6
for five generations.
Antibody Production
For production of a polyclonal antibody directed against mTERF2, a partial
peptide with high antigenicity index was produced in E. coli and purified using
aGST column (AmershamBiosciences; Fairfield, CT). Two rabbits were immu-
nized by injecting the purified peptide, followed by a boost 4 weeks later. After
exsanguinations and complement inactivation, the antibodies were affinity
purified.
For production of a monoclonal antibody directed against mTERF3, mice
were immunized by intraperitoneal injection of purified HIS-tagged mTERF3
protein coupled to a carrier, according to standard protocols (Kohler and Mil-
stein, 1975).
Submitochondrial Fractionation
For suborganellar localization, freshly isolated mitochondria from heart were
treated with three cycles of freezing-thawing and six sonication strokes at
4C. The membrane and soluble fractions were then separated by ultracentri-
fugation at 105 g for 1 hr at 4C. Mitoplasts were isolated frommitochondria by
digitonin treatment.
Isolation of Mitochondria and Measurement of OXPHOS
Complex Activity
Mitochondrial preparations were obtained as described and stored at 80C
until needed. Muscle homogenates were prepared by homogenizing a snap-
frozen muscle piece (50 mg) in 500 ml 10 mM HEPES (pH 7.4), 0.5 mM
EDTA, 0.5 mM EGTA, and 250 mM sucrose and used immediately. Enzyme
activities were determined spectrophotometrically as described (Diaz et al.,
2005). Protein concentrations were estimated by themethod of Bradford using
bovine serum albumin (BSA) as a standard.
Histochemistry and Electron Microscopy
COS cells were grown on coverslips and transfected using an expression
plasmid containing the full-length cDNA for mTERF2 and an HA tag. After
48 hr, cells were labeled with 200 nM MitoTracker (CMXRos, Molecular
Probes; Eugene, OR) for 30 min at 37C, washed with PBS and fixed with
2% paraformaldehyde, permeabilized with cold methanol, and then incubated
with anti-HA-Alexa Fluor 488-conjugated monoclonal antibody (Molecular
Probes) for 2 hr. Coverslips were mounted with an antifade aqueous mounting
gel (Biomeda; Foster City, CA), and the fluorescence was analyzed in a Carl
Zeiss (Germany) confocal microscope.
Muscle tissue was frozen in isopentane liquid nitrogen. Cross-sections
(8 mm) were stained for COX, succinate dehydrogenase (SDH), and combined
activities (Sciacco and Bonilla, 1996). Transmission electron microscopy was
performed using standard procedures.
Western Blots
Western blot analysis was performed as described (Diaz et al., 2005). Anti-
bodies against different subunits of the oxidative phosphorylation complexes
and VDAC were obtained from Molecular Probes, and an antibody against
tubulin was obtained from Chemicon International (Temecula, CA).
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Total RNA was extracted from snap-frozen muscle by TRIzol (Life Technolo-
gies; Foster City, CA). cDNA was synthesized using the SuperScript First-
Strand Kit (Invitrogen). Quantitative real-time PCR reactions were performed
on the cDNAs in the presence of fluorescent dye (SYBR Green, QIAGEN). All
results are expressed as means ± SEM. The results were normalized for
comparison by measuring b-actin mRNA levels in each sample.
Quantitative PCR for mtDNA
DNAwas isolated from tissues by chloroform/phenol extraction and incubated
with RNase A before use. mtDNA was probed with primers inside ND1 and
nuclear DNA with primer inside b-actin. Quantitative real-time PCR reactions
were performed on the cDNAs in the presence of fluorescent dye (SYBR
Green, QIAGEN). All results are expressed as means ± SEM.
Northern Blots
RNA was isolated from different tissues using TRIzol reagent (GIBCO-BRL;
Gaithersburg, MD). RNA samples were tested by ultraviolet absorption ratio
A260/A280 for purity and concentration. Values for A260/A280 were > 1.8 for all
RNA extraction. Tenmicrograms of RNA for each sample was denatured, elec-
trophoresed into a 1.5% formaldehyde agarose gel, transferred to a nylon
membrane, and crosslinked to the membrane with ultraviolet light. Hybridiza-
tion was done in Ambion solution, and washes were done according to the
manufacturer. cDNA probes were labeled with [32P]dCTP by random primer
extension (Roche) and added to the hybridizing solution. The relative content
of mRNAs was evaluated by scanning densitometry using a PhosphorImager
model 400S and ImageQuant quantitation software (Molecular Dynamics, Inc.;
Sunnyvale, CA).
High-resolution northern blotting of tRNAs was performed as described
previously (Koga et al., 1993). Forty-five-mer oligonucleotides complementary
to the tRNAs end-labeled with [g-32P]ATP were used as hybridization probes.
4.5S RNA was used as loading control.
BN Electrophoresis
BN polyacrylamide gel electrophoresis (BN-PAGE) for the identification of indi-
vidual complexes was performed as described (Nijtmans et al., 2002). Western
blots were performed as described (Diaz et al., 2005).
ATP Determination
Animals were anesthetized and muscle tissue extracted and immediately
frozen in liquid nitrogen. ATP was extracted from tissues using perchloric
acid as described (Vives-Bauza et al., 2007). ATP concentrations were deter-
mined using the luciferase-based ENLITEN ATP Assay System (Promega), and
values were normalized to milligram of tissue.
Growth Curves
To determine the growth rate of WT and mTERF2 KO fibroblasts, cells were
grown in DMEM with no glucose and 5 mM of galactose. One thousand cells
were plated in triplicates in six-well plates, trypsinized, and counted every
24hr onaZ1CoulterCell Counter (BeckmanCoulter; Fullerton,CA) over 6days.
Mitochondrial Protein Labeling
Mitochondrial protein labeling was performed in lung fibroblasts isolated from
control and KO mice as described (Chomyn, 1996).
EMSA
Mobility shift assayswere carried out using 32P-labeled probes. For TERM site,
we used previously described 44 bp oligomer (Fernandez-Silva et al., 1997).
For HSP, we used a double-stranded oligo of approximately 50 bp (16230–
16284). The reaction was performed in 25 mM HEPES (pH 7.5), 50 mM KCl,
12.5 mM MgCl2, 1 mM dithiothreitol, 20% glycerol, 0.1% Tween 20, 0.5 mg
poly(dI-dC) 3 (dI-dC), 20 fmol 50-end 32P-labeled probe, 5 mg BSA, and
100–500 ng recombinant HIS-tagged mTERF1 or mTERF2. The reaction
mixture was incubated on ice for 30 min, and immediately loaded and run in
a native 10% polyacrylamide gel in the cold room as described. After the
run, the gel was dried and analyzed by autoradiography.
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LMTK cells were stably transfected with either pcDNA3.1-mTERF2-FLAG or
pcDNA3.1-mTERF1-FLAG and grown in 16 175 cm tissue culture flasks to
80% confluency. Crosslinking, mitochondria isolation, immunoprecipitation,
and DNA isolation were carried out as described (Park et al., 2007), with the
exception that protein G magnetic beads (Invitrogen) instead of protein
A beads were used. Quantitative PCR was carried out on a 7300 Real-
Time PCR System (Applied Bioscience; Wilmington, NC) using the QIAGEN
QuantiTect SYBR Green PCR kit.
Coimmunoprecipitation Assays
For in vivo coimmunoprecipitation, LMTK cells were stably transfected with
pcDNA3.1-mTERF2-FLAG and pIREShygro-mTERF1-HA and grown in 16
175 cm tissue culture flasks to 80% confluency. Mitochondria were prepared
as previously described (Diaz et al., 2005). Mitochondria were lysed by sonica-
tion for four 15 s intervals on ice in 25 mM Tris-HCl (pH 7.4), 100 mM NaCl,
0.5% Nonidet P-40, 0.5 mM EDTA, and Roche complete protease inhibitor
mixture. The lysate was cleared by centrifugation at 16,0003 g for 30 min. Pre-
cleared lysate (400 ml) was incubated with 1 mg anti-FLAG or anti-HA antibody
overnight at 4C. Antibody-linked complexes were collected by incubation
with magnetic protein G beads for 2 hr at 4C. Magnetic beads were washed
four times in 25 mM Tris-HCl (pH 7.4) and 100 mM NaCl and eluted with SDS-
PAGE sample buffer. Western blot analysis was used to probe for FLAG-
tagged mTERF2 using monoclonal M2 FLAG antibody, for HA-tagged
mTERF1 anti-HA antibody, and for mTERF3 monoclonal mTERF3 antibody.
Blots of the input and coimmunoprecipitates were also probed with antibodies
directed against HSP60 and SDH.
For in vitro coimmunoprecipitation, HIS-tagged mTERF2 and mTERF3;
FLAG-tagged mTERF1, mTERF2, and mTERF3; and HA-tagged mTERF1
cloned into pET15b were expressed in BL21star bacteria. Bacteria were lysed
in lysis buffer (50 mM NaPi [pH 8.0], 100 mM NaCl, 10 mM imidazol, 0.05%
Tween, 1mg/ml lysozyme) by sonication (63 10 s intervals). Lysates were pre-
cleared by centrifugation 10,0003 g for 30 min. Lysates were mixed (see
Figure 7 for information), and 1 mg of mouse liver mtDNA or 1 mg of pcDNA3.1
was added. Themixture was incubated with Ni-NTAmagnetic beads for 1 hr at
RT in a total volume of 500 ml. The beads were washed four times with lysis
buffer, and the proteins were eluted with 50 mM NaPi (pH 8.0), 100 mM
NaCl, 250 mM imidazol, and 0.05% Tween. Western blot analysis was used
to probe for the affinity-tagged proteins.
In Vitro Mitochondrial Transcription Assay
Mitochondrial transcription assays were performed essentially as described
previously (Ferna´ndez-Silva et al., 1996; Wang et al., 2007), but using mito-
chondria isolated from skeletal muscle (Wenz et al., 2008) and amousemtDNA
promoter containing template. The template was a PCR product correspond-
ing to the nucleotides 15292–15970 of the mouse mtDNA encompassing LSP
and HSP. Initiation from LSP and HSP should result in transcripts of 210 and
336 nucleotide length.
Data Analysis
Data obtained are represented as means (± SD) from 3–7 mice per group, and
statistical significance was determined using Student’s t test. A p value < 0.05
was considered significant.
SUPPLEMENTAL DATA
Supplemental Data include six figures and can be found online at http://www.
cell.com/cell-metabolism/supplemental/S1550-4131(09)00122-3.
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